Login to Your Account

Leo continues foray into biologics; takes two Astrazeneca antibodies in $1B+ deal

By Cormac Sheridan
Staff Writer

Friday, July 1, 2016

DUBLIN – Leo Pharma A/S is putting biologic therapies at the heart of its strategy by making two big bets in a dermatology alliance with Astrazeneca plc under which it will take on development of tralokinumab, an interleukin-13 (IL-13) inhibitor, in atopic dermatitis, and the troubled IL-17 receptor inhibitor brodalumab in plaque psoriasis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription